Q3 Report and presentation

Tromsø, Norway, 28th October 2021 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 25.6 million (19.5) and an EBITDA of NOK 9.0 million (7.1) for the third quarter of 2021. Highlights from Q3 2021 ArcticZymes Technologies (AZT) had Q3 sales of NOK 25.6 million – an increase of 31% (Q3 2020: NOK 19.5 million) Coronavirus-related sales are estimated at …

ArcticZymes attending the 22nd World Vaccine Congress Europe in Barcelona, Spain

ArcticZymes Technologies are pleased to attend the World Vaccine Congress Europe held in Barcelona 19 – 21 October, the biggest event of this type held in Europe. You are welcome to meet Kees Linschooten, Laurent Spenle and Jørn Henriksen in person at stand 36 to discuss how our current and future enzymes can improve the vaccine manufacturing process.   

BioEntist is a new strategic distribution partner

ArcticZymes Technologies welcomes BioEntist as a strategic distribution partner for Thailand.  It supports ArcticZymes Technologies efforts to expand its commercial presence across the Asia-Pacific region. For more information about BioEntist, please click here